Treatment of Diabetic Sensory Polyneuropathy
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Opinion statementNo current disease-modifying treatments have been shown definitively in randomized clinical trials to reduce or reverse diabetic sensory polyneuropathy (DSP). It is increasingly recognized that individuals with “prediabetes” or impaired glucose regulation can already have a “small-fiber” neuropathy, or mild DSP, in which sensory axons of both small and larger diameter are damaged. Small-fiber neuropathy is frequently associated with pain, and these patients may present to a neurologist for evaluation before the underlying glucose dysregulation has been diagnosed. It is important to identify these individuals, because aggressive diabetic control and lifestyle interventions can delay the onset of diabetes and may reverse small-fiber neuropathy associated with early diabetes mellitus. Although treatment currently focuses on pain associated with DSP, attention should be paid to potential risk factors for neuropathy. For example, glycemic control and hyperlipidemia should be improved with diet, exercise, and medications. Hypertension that is a risk marker for more severe neuropathy should be treated. Angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers not only treat hypertension but also may directly reduce the progression of neuropathy. Class I or II clinical studies support the use of sodium valproate, pregabalin, duloxetine, amitriptyline, gabapentin, venlafaxine, opioids, and topical capsaicin in treating diabetic neuropathic pain. Pregabalin and gabapentin are relatively well tolerated and have few medication interactions. Sodium valproate has been shown to be effective but is not recommended for use in women of childbearing potential, and patients must be monitored for hepatotoxicity and thrombocytopenia. Tricyclic antidepressants such as amitriptyline are often used for nocturnal pain but require caution in the elderly or anyone with cardiac disease. Venlafaxine and duloxetine successfully treat neuropathic pain independently of their effect on depression. Opioid medications are associated with a high rate of adverse effects but with careful monitoring, they can be effective in treating resistant neuropathic pain. Capsaicin is an effective topical treatment that lacks systemic side effects. The lidocaine patch is effective in relieving pain associated with postherpetic neuralgia, but only class III evidence supports its use for diabetic neuropathic pain. No current Class I or II studies support other treatment modalities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Standards of medical care in diabetes 2010
American Diabetes Association (2010) · Diabetes Care · doi:10.2337/dc10-s011 · Cited by 3,470
Gæde, P., Vedel, P., Parving, H.-H., & Pedersen, O. (1999) · The Lancet · doi:10.1016/s0140-6736(98)07368-1 · Cited by 981 · cited 1×
“& In the Steno type 2 randomized study, improved glycemic control in type 2 diabetes was associated with a lower rate of progression of autonomic neuropathy [ 17 ].”
BackgroundEffect of valsartan on the incidence of diabetes and cardiovascular events
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001121 · Cited by 660
The Effect of Intensive Diabetes Therapy on the Development and Progression of Neuropathy
The Diabetes Control and Complications Trial Research Group. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-122-8-199504150-00001 · Cited by 602
Lifestyle intervention for pre-diabetic neuropathy
Smith, A. G., Russell, J., Feldman, E. L., Goldstein, J., Peltier, A., Smith, S., Hamwi, J., Pollari, D., Bixby, B., Howard, J., et al. (2006) · Diabetes Care · doi:10.2337/dc06-0224 · Cited by 585
Self-citationZiegler, D., Hanefeld, M., Ruhnau, K. J., Mei\ner, H. P., Lobisch, M., Sch�tte, K., Gries, F. A., & The ALADIN Study Group (1995) · Diabetologia · doi:10.1007/bf00400603 · Cited by 525
Microvascular complications of impaired glucose tolerance
Singleton, J. R., Smith, A. G., Russell, J. W., & Feldman, E. L. (2003) · Diabetes · doi:10.2337/diabetes.52.12.2867 · Cited by 372
Self-citationIncreased Prevalence of Impaired Glucose Tolerance in Patients With Painful Sensory Neuropathy
Singleton, J. R., Smith, A. G., & Bromberg, M. B. (2001) · Diabetes Care · doi:10.2337/diacare.24.8.1448 · Cited by 364 · cited 1×
“Neuropathic pain is also one of the most common presentations of impaired glucose regulation [9, 10].”
BackgroundPop-Busui, R., Low, P. A., Waberski, B. H., Martin, C. L., Albers, J. W., Feldman, E. L., Sommer, C., Cleary, P. A., Lachin, J. M., & Herman, W. H. (2009) · Circulation · doi:10.1161/circulationaha.108.837369 · Cited by 310
Cited by
Feldman, E. L., Callaghan, B. C., Pop-Busui, R., Zochodne, D. W., Wright, D. E., Bennett, D. L., Bril, V., Russell, J. W., & Viswanathan, V. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0092-1 · Cited by 1,697
Self-citationDiabetic neuropathic pain: Physiopathology and treatment
Schreiber, A. K. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i3.432 · Cited by 463
Updates in diabetic peripheral neuropathy
Juster-Switlyk, K., & Smith, A. G. (2016) · F1000Research · doi:10.12688/f1000research.7898.1 · Cited by 288
Emerging Relationships between Exercise, Sensory Nerves, and Neuropathic Pain
Cooper, M. A., Kluding, P. M., & Wright, D. E. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00372 · Cited by 105
“Many of these studies discussed above have centered on the ability of exercise to alleviate neuropathic pain associated with diabetes as it is the most prevalent form of neuropathic pain being investigated in hopes of improving diabetic neuropathy (Zilliox and Russell, 2011).”
BackgroundIdentification of risk factors for patients with diabetes: diabetic polyneuropathy case study
Metsker, O., Magoev, K., Yakovlev, A., Yanishevskiy, S., Kopanitsa, G., Kovalchuk, S., & Krzhizhanovskaya, V. V. (2020) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-020-01215-w · Cited by 35
Metadata
- Authors
- Zilliox, L., & Russell, J. W.
- Venue
- Current Treatment Options in Neurology
- Published
- 2011-01-28
- Volume
- 13
- Issue
- 2
- Pages
- 143-159
- ISSN
- 1092-8480 (ISSN-L)
- 1534-3138
- OpenAlex
- W2062684651
- Cited by
- 104
- References
- 12
- FWCI
- 2.70
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of Diabetic Sensory Polyneuropathy. https://app.cochat.ai/papers/10.1007/s11940-011-0113-1
- The paper
- Zilliox, L., & Russell, J. W. (2011). Treatment of Diabetic Sensory Polyneuropathy. Current Treatment Options in Neurology. https://doi.org/10.1007/s11940-011-0113-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.